RVMD ▼ -6.3% - Revolution Medicines, Inc. $RVMD Truist recommends using today's selloff in shares of Revolution Medicines as a buying opportunity. The firm attributes the pullback to newly disclosed mutation-level efficacy data in the FDA review materials showing stronger Rasonque activity in KRAS G12V than G12D. While the divergence "warrants attention," the data "offer more nuance than a fundamental challenge" to Revolution's ancreatic ductal adenocarcinoma thesis, the analyst tells investors in a research note. Truist notes that in the new data, G12D efficacy remains clinically meaningful and that the exploratory analyses were not powered for cross-mutation comparisons. It sees little change to Revolution's "competitive moat." The firm reiterates a Buy rating on the shares with a $240 price target. 08-OCT-2026 03:52 PM ET